Latest Interviews


Immunologist of the Month

Every month we feature a new interview with an Immunologist. These Immunologists are at the cutting-edge of research and education, they have kindly offered to give us their time and insight into their research and studies.


November 2024

Dr Shubhada Chiplunkar is a distinguished immunologist and researcher with over 35 years of experience in cancer biology and immunology. She is the former Director of the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) at the Tata Memorial Centre in Navi Mumbai, where she also led the Cancer Immunology and Immunotherapy Research Group. Dr Chiplunkar has made significant contributions to the field of cancer immunotherapy, particularly in deciphering the role of tumour microenvironment in shaping anti-tumour gamma delta T cell responses in various malignancies.

Dr Chiplunkar is a member of several scientific advisory and review committees of national research institutes. Currently, she is the President of the Immuno-oncology Society of India (IOSI) and the Mumbai Immunology Group (MIG), and a member of the International Union of Immunological Societies (IUIS) Education (EDU) Committee.

Read more – Shubhada Chiplunkar


October 2024

Monica L. Guzman, PhD is an Associate Professor of Pharmacology in Medicine in the Division of Haematology and Medical Oncology and Assistant Director of Diversity Equity and Inclusion of Basic and Translational Science in the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine (WCM), USA.

Monica was listed among 100 inspiring Hispanic/Latinx scientists in America in 2020 and was Included in Hispanic Role Models in Science: Advice for Future Scientists by Paola Mina-Osorio. She was included in “Ciencia y Vida,” a compilation of 36 Outstanding Mexican Scientists by Hector Mayani in 2023.

Dr Guzman’s lab aims to identify vulnerabilities in malignant stem/progenitor cells, measure residual disease, assess the tumour microenvironment, and identify therapeutic approaches to eliminate malignant cells without harming their normal counterparts.

Read more – Monica Guzman

 

 
 
 
 
 
 
International Union of Immunological SocietiesUniversity of South AfricaInstitute of Infectious Disease and Molecular MedicineElizabeth Glazer Pediatric Aids Foundation